Potent Human Monoclonal Antibodies Against SARS CoV, Nipah and Hendra Viruses

Expert Opinion on Biological Therapy - United Kingdom
doi 10.1517/14712590902763755
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa Healthcare

Related search

Fully Human Single-Domain Antibodies Against SARS-CoV-2

2020English

Monoclonal Antibodies for the S2 Subunit of Spike of SARS-CoV Cross-React With the Newly-Emerged SARS-CoV-2

2020English

Human Monoclonal Antibodies Block the Binding of SARS-CoV-2 Spike Protein to Angiotensin Converting Enzyme 2 Receptor

2020English

Potential Host Range of Multiple SARS-like Coronaviruses and an Improved ACE2-Fc Variant That Is Potent Against Both SARS-CoV-2 and SARS-CoV-1

2020English

On the Interactions of the Receptor-Binding Domain of SARS-CoV-1 and SARS-CoV-2 Spike Proteins With Monoclonal Antibodies and the Receptor ACE2

2020English

Detection of Antibodies Against SARS-CoV-2 in Patients With COVID-19

Journal of Medical Virology
VirologyInfectious Diseases
2020English

RNA Genome Conservation and Secondary Structure in SARS-CoV-2 and SARS-related Viruses

2020English

Virus Against Virus: A Potential Treatment for 2019-nCov (SARS-CoV-2) and Other RNA Viruses

Cell Research
Cell BiologyMolecular Biology
2020English

Initial Characterization of Monoclonal Antibodies Against Human Monocytes.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1980English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy